B’SYS has developed the NMDA DUO™ cell line series, featuring co-expression of human NMDA receptor subunits in HEK cells. Specific combinations of GluN1 (GRIN1; NP_015566) with defined GluN2 subunits (e.g., GluN2A–D) were cloned and stably transfected into HEK293 cells. Functional receptor expression was validated using manual and automated patch-clamp techniques, including QPatch™. If you intend to purchase one or more of the cell lines for commercial or academic research under the B’SYS standard use licenses, please contact us.

NMDA (N-methyl-D-aspartate) receptors are ionotropic glutamate receptors that play a key role in synaptic plasticity, learning, and memory. Functional NMDA receptors are heterotetramers composed of two GluN1 and typically two GluN2 subunits, with the specific GluN2 subtype (A–D) critically influencing receptor kinetics, ion permeability, and pharmacological profile.

The B’SYS NMDA DUO™ cell lines allow the controlled expression of defined subunit combinations to study receptor subtype-specific behavior under reproducible conditions. These receptors are voltage-dependent and ligand-gated, requiring both glutamate and glycine binding, as well as depolarization to relieve magnesium block—making them highly regulated signaling hubs in the CNS.

Dysregulation of NMDA receptor activity has been implicated in various neurological and psychiatric conditions, including schizophrenia, Alzheimer’s disease, epilepsy, and excitotoxic neuronal damage following stroke or trauma. The NMDA DUO™ series provides a valuable tool for screening subtype-selective modulators, studying pathophysiological mechanisms of receptor dysfunction, and supporting CNS-targeted drug discovery.